Curis soars after FDA lifts partial clinical hold on lymphoma drug trial

Curis

18/08/2022 13:50

** Shares of Curis Inc  CRIS.O  rise 29.5% to $1.36
premarket - on track to open at an over four-month high if gains
hold; among top pct gainers across U.S. exchanges
    ** CRIS says the U.S. FDA lifted its partial clinical hold
on an early-to-mid-stage trial testing company's drug candidate,
 emavusertib, for lymphoma, a cancer of the lymphatic system
 urn:newsml:reuters.com:*:nPn4Dk7T0a
    ** In April, the FDA had placed a partial clinical hold on
another trial of emavusertib for blood cancer after the death of
a patient who experienced rhabdomyolysis, or muscle tissue
breakdown  urn:newsml:reuters.com:*:nL3N2W21O7
    ** CRIS had voluntarily paused enrollment in the lymphoma
study after the hold on the leukemia trial; the FDA later also
put a hold on the lymphoma trial  urn:newsml:reuters.com:*:nL3N2W92LI
    ** CRIS says FDA agreed with its strategy on rhabdomyolysis
identification and management; expects to resume enrollment of
new patients in the lymphoma study in Q3
    ** Up to the last close, CRIS had fallen 78% YTD vs a 12.6%
decline in the Nasdaq biotech index  .NBI 

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))